The case for routine parathyroid hormone monitoring

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 2, 2013, Pages 313-318

  Sprague, Stuart M ^a   Moe, Sharon M ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; ERYTHROPOIETIN; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR 1; PHOSPHATE; PHOSPHORUS; VITAMIN D;

ARTICLE; CARDIOMYOPATHY; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; HUMAN; HYPERPARATHYROIDISM; KIDNEY FAILURE; MONITORING; MORBIDITY; MORTALITY; MYOPATHY; NEUROLOGIC DISEASE; NONHUMAN; PARATHYROIDECTOMY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION;

DIAGNOSTIC TESTS, ROUTINE; HEMATOLOGIC TESTS; HUMANS; PARATHYROID HORMONE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84875030925     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04650512     Document Type: Article

References (56)

1. Albright F, Drake TG, Sulkowitch HW: Renal osteitis fibrosa cystica. Report of a case with discussion of metabolic aspects. Bull Johns Hopkins Hosp 60: 377-399, 1937
2. Slatopolsky E, Caglar S, Pennell JP, Taggart DD, Canterbury JM, Reiss E, Bricker NS: On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 50: 492-499, 1971
3. Bricker NS: On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". N Engl J Med 286: 1093-1099, 1972
4. Malluche HH, Bellorin-Font ER, Rojas E, Carvalho AB, D'Haese PC, Drueke TB, Ferreira MA, Jorgetti V, Moe SM, Sprague SM: Predictive value of biomarkers for bone turnover in ESKD [Abstract]. J Am Soc Nephrol 21: 778A, 2010
5. Nichols P, Owen JP, Ellis HA, Farndon JR, Kelly PJ, Ward MK: Parathyroidectomy in chronic renal failure: A nine-year followup study. Q J Med 77: 1175-1193, 1990
6. Katz A, Lattes R: Granulomatous thymoma or Hodgkin's disease of thymus? A clinical and histologic study and a re-evaluation. Cancer 23: 1-15, 1969
7. Yajima A, Ogawa Y, Takahashi HE, Tominaga Y, Inou T, OtsuboO: Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kidney Dis 42: 729-738, 2003
8. Stein MS, Packham DK, Wark JD, Becker GJ: Response to parathyroidectomy at the axial and appendicular skeleton in renal patients. Clin Nephrol 52: 172-178, 1999
9. Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B: Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18: 2401-2407, 2007
10. Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, Stehman-Breen C: Survival following parathyroidectomyamongUnited States dialysis patients. Kidney Int 66: 2010-2016, 2004
11. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274-279, 1989
12. Fukagawa M, Okazaki R, Takano K, Kaname S, Ogata E, Kitaoka M, Harada S, Sekine N, Matsumoto T, Kurokawa K: Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. [letter] N Engl J Med 323: 421-422, 1990
13. Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Jüppner H, Salusky IB: Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 79: 112-119, 2011
14. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53: 448-453, 1998
15. Moe SM, Seifert MF, Chen NX, Sinders RM, Chen X, Duan D, Henley C, Martin D, Gattone VH 2nd: R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrol Dial Transplant 24: 2371-2377, 2009
16. Yajima A, Akizawa T, Tsukamoto Y, Kurihara S, Ito A; K Study Group: Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism. Ther Apher Dial 12[Suppl 1]: S38-S43, 2008
17. Twelve-month study of AMG073 in renal osteodystrophy. Available at: http://clinicaltrials.gov/ct2/show/NCT00527085. Accessed August 27, 2012
18. Stickler GB, Bergen BJ: A review: Short stature in renal disease. Pediatr Res 7: 978-982, 1973
19. MehlsO, Ritz E, Krempien B, GilliG, Link K, Willich E, Schärer K: Slipped epiphyses in renal osteodystrophy. Arch Dis Child 50: 545-554, 1975
20. Eastwood JB, Bordier PJ, de Wardener HE: Some biochemical, histological, radiological and clinical features of renal osteodystrophy. Kidney Int 4: 128-140, 1973
21. Lazaro RP, Kirshner HS: Proximal muscle weakness in uremia. Case reports and review of the literature. Arch Neurol 37: 555-558, 1980
22. LotemM, BerheimJ, Conforty B: Spontaneous rupture of tendons. A complication of hemodialyzed patients treated for renal failure. Nephron 21: 201-208, 1978
23. Vanholder R, Argiles A, BaurmeisterU, Brunet P, ClarkW, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodroguez M, Stegmayr B, Stenvinkel P, Wratten ML: Uremic toxicity: Present state of the art. Int J Artif Organs 24: 695-725, 2001
24. Massry SG, Smogorzewski M: Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14: 219-231, 1994
25. Bogin E, Massry SG, Harary I: Effect of parathyroid hormone on rat heart cells. J Clin Invest 67: 1215-1227, 1981
26. Guisado R, Arieff AI, Massry SG, Lazarowitz V, Kerian A: Changes in the electroencephalogram in acute uremia. Effects of parathyroid hormone and brain electrolytes. J Clin Invest 55: 738-745, 1975
27. Akmal M, Goldstein DA, Multani S, Massry SG: Role of uremia, brain calcium, and parathyroid hormone on changes in electroencephalogram in chronic renal failure. Am J Physiol 246: F575-F579, 1984
28. Akmal M, Barndt RR, Ansari AN, Mohler JG, Massry SG: Excess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy. Kidney Int 47: 158-163, 1995
29. Goldstein DA, Feinstein EI, Chui LA, Pattabhiraman R, Massry SG: The relationship between the abnormalities in electroencephalogram and blood levels of parathyroid hormone in dialysis patients. J Clin Endocrinol Metab 51: 130-134, 1980
30. Cogan MG, Covey CM, Arieff AI, Wisniewski A, Clark OH, Lazarowitz V, LeachW: Central nervous system manifestations of hyperparathyroidism. Am J Med 65: 963-970, 1978
31. AvramMM, FeinfeldDA, HuatucoAH: Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia. N Engl J Med 298: 1000-1003, 1978
32. Avram MM, Iancu M, Morrow P, Feinfeld D, Huatuco A: Uremic syndrome in man: New evidence for parathormone as a multisystem neurotoxin. Clin Nephrol 11: 59-62, 1979
33. RaoDS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328: 171-175, 1993
34. MeytesD, Bogin E, MaA, Dukes PP, Massry SG: Effect of parathyroid hormone on erythropoiesis. J Clin Invest 67: 1263-1269, 1981
35. Ureña P, Eckardt KU, Sarfati E, Zingraff J, Zins B, Roullet JB, Roland E, Drüeke T, Kurtz A: Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: Effect of parathyroidectomy. Nephron 59: 384-393, 1991
36. Kleeman CR, Massry SG, Popovtzer MM, Makoff DL, Maxwell MH, Coburn JW: The disappearance of intractable pruritus after parathyroidectomy in uremic patients with secondary hyperparathyroidism. Trans Assoc Am Physicians 81: 203-212, 1968
37. Goldsmith DJ, Covic AA, Venning MC, Ackrill P: Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: Further evidence implicating calcium homeostasis in blood pressure regulation. Am J Kidney Dis 27: 819-825, 1996
38. Drüeke T, Fauchet M, Fleury J, Lesourd P, Toure Y, Le Pailleur C, de Vernejoul P, Crosnier J: Effect of parathyroidectomy on left-ventricular function in haemodialysis patients. Lancet 1: 112-114, 1980
39. Fellner SK, Lang RM, Neumann A, Bushinsky DA, Borow KM: Parathyroid hormone and myocardial performance in dialysis patients. Am J Kidney Dis 18: 320-325, 1991
40. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, SellmeyerD, Eriksen EF, Cummings SR;HORIZONPivotal Fracture Trial: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl JMed 356: 1809-1822, 2007
41. Cummings SR, San Martin J, McClungMR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756-765, 2009
42. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33: 73-81, 1999
43. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, AndressD, ZhangW, PackhamD, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 307: 674-684, 2012
44. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J; ADVANCE Study Group: The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26: 1327-1339, 2011
45. Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhães AO, CustódioMR, Batista DG, Jorgetti V, Moysés RM: Vascular calcification: Contribution of parathyroid hormone in renal failure. Kidney Int 71: 1262-1270, 2007
46. Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, Niederle B: Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up. J Clin Endocrinol Metab 82: 106-112, 1997
47. Gipstein RM, Coburn JW, Adams DA, Lee DB, Parsa KP, Sellers A, Suki WN, Massry SG: Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med 136: 1273-1280, 1976
48. Rogers NM, Teubner DJ, Coates PT: Calcific uremic arteriolopathy: Advances in pathogenesis and treatment. Semin Dial 20: 150-157, 2007
49. Herberth J, Monier-Faugere MC, Mawad HW, Branscum AJ, Herberth Z, Wang G, Cantor T, Malluche HH: The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients. Clin Nephrol 72: 5-14, 2009
50. Cole DE, Webb S, Chan PC: Update on parathyroid hormone: New tests and new challenges for external quality assessment. Clin Biochem 40: 585-590, 2007
51. Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL: Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16: 605-614, 2001
52. Taniguchi M, Tanaka M, Hamano T, Nakanishi S, Fujii H, Kato H, Koiwa F, Ando R, Kimata N, Akiba T, Kono T, Yokoyama K, Shigematsu T, Kakuta T, Kazama JJ, Tominaga Y, Fukagawa M: Comparison between whole and intact parathyroid hormone assays. Ther Apher Dial 15[Suppl 1]: 42-49, 2011
53. KDIGO: Clinical Practice Guidelines for the Management of CKD-MBD. Kidney Int 76: S1-S130, 2009
54. Gardham C, Stevens PE, Delaney MP, LeRoux M, Coleman A, Lamb EJ: Variability of parathyroid hormone and othermarkers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol 5: 1261-1267, 2010
55. Almond A, Ellis AR, Walker SW; Scottish Clinical Biochemistry Managed Diagnostic Network: Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann Clin Biochem 49: 63-67, 2012
56. EVOLVE Trial: Evaluation of cinacalcet HCl therapy to lower cardiovascular events. Available at: http://clinicaltrials.gov/ct2/show/NCT00345839. Accessed August 27, 2012